Biocon (BIOCON) Aktievy
Biocon Limited, tillsammans med sina dotterbolag, bedriver tillverkning och försäljning av biotekniska produkter och forskningstjänster i Indien, Brasilien, Singapore och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 3/6 |
| Framtida tillväxt | 4/6 |
| Tidigare resultat | 1/6 |
| Finansiell hälsa | 4/6 |
| Utdelningar | 0/6 |
BIOCON Community Fair Values
Create NarrativeSee what 25 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Biocon Limited Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | ₹424.30 |
| 52 veckors högsta | ₹440.40 |
| 52 veckors lägsta | ₹331.00 |
| Beta | 0.32 |
| 1 månads förändring | 2.91% |
| 3 månaders förändring | 24.78% |
| 1 års förändring | 14.03% |
| 3 års förändring | 66.59% |
| 5 års förändring | 9.54% |
| Förändring sedan börsintroduktionen | 951.87% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Jun 15
BIOCON: Future Margin Reset Will Support Biosimilars Expansion And Leadership Transition
Narrative Update Analysts have trimmed Biocon's fair value estimate to ₹506.0 from ₹544.20 as they reset expectations around profit margin assumptions and a higher future P/E, while also fine tuning discount rate and revenue growth inputs. Analyst Commentary Recent Street commentary around related life sciences companies highlights how bullish analysts think about valuation resets, margin potential and recovery timelines.
Uppdatering av berättelse • Jun 01
BIOCON: Tough Macro And Execution Risks Will Restrict Future P/E Upside
Analysts have nudged their fair value estimate for Biocon slightly higher to about ₹299 from roughly ₹296, reflecting updated assumptions for discount rate, revenue growth, profit margins and future P/E multiples. The rationale is informed by recent Street research on peer companies that highlights the impact of tougher macro conditions, underappreciated balance sheet items and potential margin improvements under refreshed management teams.Analysartikel • May 21
Biocon's (NSE:BIOCON) Weak Earnings May Only Reveal A Part Of The Whole Picture
The subdued market reaction suggests that Biocon Limited's ( NSE:BIOCON ) recent earnings didn't contain any surprises...Recent updates
Uppdatering av berättelse • Jun 15
BIOCON: Future Margin Reset Will Support Biosimilars Expansion And Leadership Transition
Narrative Update Analysts have trimmed Biocon's fair value estimate to ₹506.0 from ₹544.20 as they reset expectations around profit margin assumptions and a higher future P/E, while also fine tuning discount rate and revenue growth inputs. Analyst Commentary Recent Street commentary around related life sciences companies highlights how bullish analysts think about valuation resets, margin potential and recovery timelines.Uppdatering av berättelse • Jun 01
BIOCON: Tough Macro And Execution Risks Will Restrict Future P/E Upside
Analysts have nudged their fair value estimate for Biocon slightly higher to about ₹299 from roughly ₹296, reflecting updated assumptions for discount rate, revenue growth, profit margins and future P/E multiples. The rationale is informed by recent Street research on peer companies that highlights the impact of tougher macro conditions, underappreciated balance sheet items and potential margin improvements under refreshed management teams.Analysartikel • May 21
Biocon's (NSE:BIOCON) Weak Earnings May Only Reveal A Part Of The Whole Picture
The subdued market reaction suggests that Biocon Limited's ( NSE:BIOCON ) recent earnings didn't contain any surprises...
Uppdatering av berättelse • May 03
BIOCON: Leadership Changes And Biosimilars Expansion Will Support Future Upside
Biocon's analyst price target has been trimmed slightly to about ₹416 from roughly ₹421 as analysts factor in a marginally higher discount rate, slightly softer revenue growth and profit margin assumptions, partly balanced by a modestly higher future P/E multiple. Analyst Commentary Recent Street research around comparable life sciences names points to a cautious tone on execution risk, revenue trajectory and the willingness of the market to pay up for growth after guidance disappointments.Uppdatering av berättelse • Apr 19
BIOCON: Higher Profitability Assumptions Will Support U.S. Biosimilars And GLP-1 Entry
Narrative Update on Biocon Analysts have adjusted their price target on Biocon to ₹544, up from ₹465. This reflects updated assumptions around a higher fair value estimate, revised profit margin expectations, and a slightly different discount rate and forward P/E framework.Uppdatering av berättelse • Apr 05
BIOCON: Leadership Refresh And Biosimilars Integration Will Support Future Upside
Analysts have trimmed Biocon's fair value estimate slightly to ₹420.74 from ₹421.60, reflecting updated assumptions around the discount rate, revenue growth, profit margins and future P/E expectations. Analyst Commentary Analysts are treating the trimmed fair value estimate as a fine tuning of expectations rather than a major reset, with views split between what could support upside and what might cap near term returns.Uppdatering av berättelse • Mar 21
BIOCON: Limited P/E Expansion Will Constrain Returns Despite New Metabolic Drug Approvals
Analysts have trimmed their Biocon price target slightly to about ₹295.70 from roughly ₹297.40, reflecting a modest recalibration of fair value, discount rate and long term assumptions for revenue growth, profit margin and future P/E multiples. Analyst Commentary Bearish analysts trimming Biocon's fair value signal a more careful stance on what they are willing to pay for the shares today, given reassessed views on growth, profitability and valuation multiples.Uppdatering av berättelse • Mar 07
BIOCON: Limited Multiple Expansion Will Constrain Returns Despite New GLP 1 Approvals
Narrative update Analysts have trimmed their Biocon price target slightly to about ₹297 from roughly ₹298, reflecting updated assumptions on discount rate, revenue growth, profit margins and future P/E multiples after recent sector research signalled a more cautious stance on multiple expansion. Analyst Commentary Bearish analysts looking at global life sciences peers have trimmed price targets after recent earnings misses and cautious forward commentary, and those moves are informing how some investors think about Biocon's risk and valuation setup.Uppdatering av berättelse • Feb 21
BIOCON: Execution And Multiple Compression Risks Will Restrain Future Share Returns
Analysts have inched up their Biocon fair value estimate to about ₹298 per share from roughly ₹295, reflecting slightly lower discount rate assumptions, modestly softer revenue growth expectations, a somewhat stronger profit margin outlook, and a marginally reduced future P/E multiple. Analyst Commentary While the fair value adjustment for Biocon is modest, some bearish analysts are still flagging risks that could cap upside in the near term.Uppdatering av berättelse • Feb 07
BIOCON: Equity Dilution And Biosimilars Review Will Pressure Future Returns
Analysts have slightly reduced their Biocon fair value estimate to ₹295.12 from ₹296.78, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E multiples. What's in the News Biocon completed a follow on equity offering of equity shares worth ₹41.5b, issuing 112,664,585 common shares at ₹368.35 each under a Regulation S structure with a subsequent direct listing (company filing).Uppdatering av berättelse • Jan 23
BIOCON: Biosimilars Reorganisation And GLP 1 Expansion Will Drive Future Upside
Analysts have nudged their fair value estimate for Biocon higher from ₹412.05 to ₹421.60, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E multiples in their valuation work. What's in the News Biocon completed a follow on equity offering of ₹41.5b, issuing 112,664,585 equity shares at ₹368.35 per share under Regulation S, followed by a subsequent direct listing (Key Developments).Uppdatering av berättelse • Jan 09
BIOCON: Planned Capital Raise Will Likely Weigh On Future Shareholder Returns
Analysts have lifted their price target on Biocon from ₹290.00 to about ₹296.78, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and forward P/E inputs in their models. What's in the News Shareholders approved amendments to Biocon's Articles of Association at the AGM held on December 31, 2025, signaling changes to the company's governing documents (Key Developments).Uppdatering av berättelse • Dec 26
BIOCON: Future Equity Issuance Will Likely Pressure Shareholder Returns
Analysts have maintained their fair value estimate for Biocon at ₹290.00 per share, with only minor model adjustments to discount rate, revenue growth, and profit margin assumptions. These changes have resulted in no alteration to their overall price target, as they continue to view the company’s long term earnings profile as broadly intact.Analysartikel • Dec 25
Calculating The Fair Value Of Biocon Limited (NSE:BIOCON)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Biocon fair value estimate is ₹364 With ₹398 share price...Uppdatering av berättelse • Dec 12
BIOCON: Future Share Dilution Risk Will Likely Pressure Returns
Analysts have raised their price target on Biocon from ₹277.50 to ₹290.00, reflecting higher anticipated revenue growth, improved profit margins, and a modestly re-rated future P E multiple despite a slightly higher discount rate. What's in the News Biocon is exploring strategic options for its biosimilars arm Biocon Biologics Limited, including a potential merger with the parent company in place of an IPO, with Morgan Stanley advising on value creation alternatives (Key Developments).Analysartikel • Dec 07
Investors Don't See Light At End Of Biocon Limited's (NSE:BIOCON) Tunnel
You may think that with a price-to-sales (or "P/S") ratio of 3.2x Biocon Limited ( NSE:BIOCON ) is a stock worth...Uppdatering av berättelse • Nov 27
BIOCON: Global Expansion And Business Restructuring Are Expected To Balance Opportunities And Risks
Analysts have raised their price target for Biocon from ₹395.65 to ₹412.05. This change reflects updated expectations around key valuation inputs and profitability metrics.Analysartikel • Nov 19
Weak Statutory Earnings May Not Tell The Whole Story For Biocon (NSE:BIOCON)
The market rallied behind Biocon Limited's ( NSE:BIOCON ) stock, leading do a rise in the share price after its recent...Uppdatering av berättelse • Nov 13
BIOCON: Revenue Outlook And Global Expansion Likely To Support Steady Performance
Analysts have raised Biocon's fair value price target from ₹376.70 to ₹395.65, citing improved revenue growth projections and profit margins as key drivers for the upgrade. What's in the News Biocon announced the public funding of YESAFILI (aflibercept), a biosimilar to EYLEA, on the Ontario Drug Benefit Formulary in Canada for retinal disease treatment.Uppdatering av berättelse • Oct 05
Biosimilars Demand Will Unlock Global Market Opportunities
Analysts have lowered Biocon's price target slightly from ₹380.11 to ₹376.70, citing marginal adjustments in the discount rate and projected earnings metrics. Analyst Commentary Market watchers have weighed in on Biocon's valuation following the recent adjustment to its price target.Analysartikel • Sep 22
Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 56% Above Its Share Price
Key Insights The projected fair value for Biocon is ₹577 based on 2 Stage Free Cash Flow to Equity Biocon's ₹369 share...Analysartikel • Aug 10
Biocon Limited Just Missed Earnings - But Analysts Have Updated Their Models
NSEI:BIOCON 1 Year Share Price vs Fair Value Explore Biocon's Fair Values from the Community and select yours There's...Analysartikel • Aug 04
Pinning Down Biocon Limited's (NSE:BIOCON) P/E Is Difficult Right Now
Biocon Limited's ( NSE:BIOCON ) price-to-earnings (or "P/E") ratio of 50.5x might make it look like a strong sell right...
Ny berättelse • Dec 12
Tactical Biosimilars Expansion And Viatris Integration Will Propel Revenue Growth And Boost Profitability
Strategic cost improvements and production efficiencies are set to enhance margins and profitability in the generics segment.Aktieägarnas avkastning
| BIOCON | IN Biotechs | IN Marknad | |
|---|---|---|---|
| 7D | 2.2% | 2.2% | 1.0% |
| 1Y | 14.0% | 13.5% | -1.4% |
Avkastning vs industri: BIOCON matchade Indian Biotechs branschen som gav 13.5 % under det senaste året.
Avkastning vs Marknaden: BIOCON översteg Indian marknaden som gav -1.4 % under det senaste året.
Prisvolatilitet
| BIOCON volatility | |
|---|---|
| BIOCON Average Weekly Movement | 3.3% |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.3% |
| 10% least volatile stocks in IN Market | 4.1% |
Stabil aktiekurs: BIOCON har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för Indian.
Volatilitet över tid: BIOCON s veckovolatilitet ( 3% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1978 | 16,420 | Shreehas Tambe | www.biocon.com |
Biocon Limited, tillsammans med sina dotterbolag, bedriver tillverkning och försäljning av biotekniska produkter och forskningstjänster i Indien, Brasilien, Singapore och internationellt. Verksamheten bedrivs genom fyra segment: Generics, Novel Biologics, Biosimilars och Research Services. Företaget erbjuder generiska formuleringar och API-produkter, inklusive antidiabetika, immunsuppressiva medel, multipel skleros, cancer/onkologi och andra produkter; nya biologiska produkter, såsom huvud- och halscancermolekyler; nya produkter i forskningsportföljen som omfattar psoriasismolekyler; och biosimilarprodukter som består av insuliner, trastuzumab, pegfilgrastim och bevacizumab.
Biocon Limited Sammanfattning av grunderna
| BIOCON grundläggande statistik | |
|---|---|
| Börsvärde | ₹686.67b |
| Vinst(TTM) | ₹3.86b |
| Intäkter(TTM) | ₹169.27b |
178.1x
P/E-förhållande4.1x
P/S-förhållandeÄr BIOCON övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| BIOCON resultaträkning (TTM) | |
|---|---|
| Intäkter | ₹169.27b |
| Kostnad för intäkter | ₹56.91b |
| Bruttovinst | ₹112.36b |
| Övriga kostnader | ₹108.51b |
| Intäkter | ₹3.86b |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | 2.38 |
| Bruttomarginal | 66.38% |
| Nettovinstmarginal | 2.28% |
| Skuld/egenkapitalförhållande | 40.5% |
Hur har BIOCON utvecklats på lång sikt?
Se historisk utveckling och jämförelseUtdelningar
0.1%
Aktuell utdelningsavkastning18%
UtbetalningskvotGer BIOCON en tillförlitlig utdelning?
Se BIOCON utdelningshistorik och jämförelsetal| Biocon datum för utdelning | |
|---|---|
| Ex utdelningsdag | Jul 03 2026 |
| Utbetalningsdag för utdelning | Aug 31 2026 |
| Dagar till Ex-utdelning | 4 days |
| Dagar till utdelningsdag | 55 days |
Ger BIOCON en tillförlitlig utdelning?
Se BIOCON utdelningshistorik och jämförelsetalFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/06 21:41 |
| Aktiekurs vid dagens slut | 2026/07/06 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2026/03/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Biocon Limited bevakas av 39 analytiker. 18 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Meeta Shetty | Asian Markets Securities Private Limited |
| Harith Ahamed | Avendus Spark |